Executive and Scientific Leadership Team
Kent Pryor, PhD, MBA
Chief Executive Officer and Executive Director​
Kent Pryor is a Director and Chief Executive Officer of ZZ Biotech. Previously, he served as Chief Operating Officer of SynthRx, Inc., Associate Director of Drug Development at Kémia, Inc., and Group Leader at Corvas International, Inc.
​
Dr Pryor received his BA in chemistry magna cum laude from Rice University, a PhD in organic chemistry from the Massachusetts Institute of Technology, and an MBA from the Rady School of Management at the University of California, San Diego.
​
Meagan Walsh, BSc (Hons), PhD
Chief Operating Officer and Executive Director​
Meagan Walsh is a Director for Novapep and ProKardia. Previously, she held the role as Novartis Regional Medical Director (Immunology), Asia Pacific, Middle East & Africa and as Novartis Chief Scientific Officer, Singapore and Asian Emerging Markets. ​
​
​Dr Walsh has a BSc and a PhD in Molecular Biochemistry and Statistics from the University of Queensland where her research interests focused on inflammatory diseases of the liver.
Prof Greg Fulcher, MBBS, MD, FRACP
Chief Medical Officer
Greg Fulcher is Clinical Professor of Medicine and Director of Diabetes, Endocrinology & Metabolism at Royal North Shore Hospital, Sydney​. As a senior clinician, he has made significant contributions to the fields of internal medicine and endocrinology, with a particular focus on diabetes management and healthcare leadership. He has authored more than 100 scientific articles, reviews and book chapters.​ Prof Fulcher is on the Global Advisory Board for Novo Nordisk and National Advisory Boards of Novo Nordisk, MSD, AstraZeneca, Bristol Myers-Squibb, Boehringer Ingelheim and Sanofi.​
Prof Chris Jackson, BAppSc, MAppSc, PhD
Chief Scientific Officer
Chris Jackson is Professor of Regenerative Science and Medicine, Kolling Institute, University of Sydney​ and the co-developer of APC as a wound healing agent. His career has been centered around advancing the understanding and application of regenerative medicine, a field that seeks to repair or replace damaged tissues and organs through innovative techniques. As a researcher in wound healing and inflammation, he has over 130 scientific publications.​
Prof John Griffin, MS, PhD
Chairman of the Scientific Advisory Board
John Griffin is the developer of 3K3A-Activated Protein C. Renowned for his groundbreaking work in the field of hemostasis, thrombosis, and vascular biology, he has been a prominent faculty member at The Scripps Research Institute, where his research has significantly advanced the understanding of the protein C pathway and its role in anticoagulation, inflammation, and cell signaling. More than 250 of his 450 scientific publications involve studies of Activated Protein C. In 1994, he was awarded a 10 year National Institutes of Health MERIT award grant for studies of Activated Protein C. In 2005, he was awarded the International Society on Thrombosis & Hemostasis Career Achievement Award.
